In the evolving landscape of regenerative medicine, mitochondrial transplantation emerges as a startlingly promising approach. This novel concept involves isolating intact, functional mitochondria and delivering them into cells experiencing mitochondrial insufficiency. Unlike gene or stem cell therapies, mitochondrial transplantation aims to rapidly reconstitute bioenergetics without genetically altering the host cell. However, despite encouraging preliminary findings in animal and cellular models, a fundamental understanding of how transplanted mitochondria interface with recipient cells remains elusive. Do these organelles penetrate the cellular membrane and integrate functionally? If so, through which cellular uptake mechanisms? And critically, can they sustain their bioenergetic roles once internalized?

A landmark study recently addressed these pivotal questions with unprecedented rigor. Led by Associate Professor Kosuke Kusamori at Tokyo University of Science, the research employed mesenchymal stromal cells (MSCs)—a cell type renowned for regenerative potential—as recipients for isolated mitochondria. By amalgamating advanced imaging modalities—including fluorescence microscopy, confocal imaging, flow cytometry, and electron microscopy—with comprehensive biochemical assays, the investigators mapped the trajectory and function of exogenous mitochondria within MSCs. This multifaceted approach allowed precise visualization and quantification of mitochondrial uptake, as well as functional assessments post internalization.

Initial experiments focused on the isolation of mitochondria while preserving their ultrastructure and functional capacity. The mitochondria extracted from MSCs demonstrated high purity, devoid of contaminants such as other cellular organelles or debris. Importantly, these isolated mitochondria retained robust ATP synthesis ability, indicating preserved bioenergetic integrity during the isolation process. Subsequent provision of these mitochondria to living MSCs and hepatocytes yielded remarkable enhancements in cellular health. Notable outcomes included increased cell proliferation rates and improved resistance to oxidative and chemical stressors, reflecting the mitochondria’s cytoprotective effect.

A central question was whether these beneficial effects required actual mitochondrial internalization by recipient cells. Time-course studies revealed a gradual, time-dependent uptake of mitochondria by MSCs, reaching significant intracellular accumulation over several hours. Electron microscopic analysis showcased mitochondria entrapped within membrane-bound vesicles inside the cytoplasm, confirming true internalization rather than superficial adherence. By employing specific pharmacological inhibitors to block clathrin-, caveolin-, CLIC/GEEC-, and actin-mediated endocytic pathways, the research uncovered that MSCs utilize multiple, overlapping mechanisms to engulf transplanted mitochondria. This multiplicity underscores a complex, multifaceted cellular uptake process differing from single-pathway endocytosis found in many other biological processes.

Functional assays corroborated that the internalized mitochondria remained bioenergetically active. MSCs receiving mitochondrial transplants demonstrated enhanced mitochondrial respiration, evaluated by oxygen consumption rate measurements, alongside increased ATP production. These effects displayed a dose-responsive relationship to mitochondrial concentration, emphasizing the therapeutic potential of modulating mitochondrial doses. The enhanced respiratory capacity, coupled with heightened proliferation and stress resistance, suggests that transplanted mitochondria can more than simply survive within host cells—they actively improve cellular metabolic competence.

The elucidation of these uptake pathways and their biological consequences lays a crucial foundation for advancing mitochondrial transplantation from bench to bedside. By harnessing natural endocytic routes, therapeutic protocols can be optimized to maximize mitochondrial delivery efficiency. Such precision could enable tailored approaches adapted to the unique endocytic profiles of different cell types or pathological states. Moreover, confirming that transplanted mitochondria retain functionality challenges previous skepticism regarding their intracellular fate and offers compelling evidence for mitochondrial therapy as a distinct biomedical field.

Currently, mitochondrial transplantation remains in preclinical research, with many regulatory, safety, and efficacy hurdles to overcome. Long-term studies are needed to assess the persistence and integration of transplanted mitochondria, potential immune responses, and effects on tissue homeostasis across diverse disease models. Ensuring the purity, consistency, and biological activity of isolated mitochondria is paramount for clinical translation. Nonetheless, the non-genetic nature of this approach could provide rapid interventions for acute mitochondrial failure, circumventing complexities linked to gene editing or stem cell integration.

The therapeutic applications of mitochondrial transplantation are vast and especially poignant in diseases marked by mitochondrial defects. Ischemia–reperfusion injury following heart attacks or strokes, neurodegenerative conditions such as Parkinson’s and Alzheimer’s diseases, and toxin-induced hepatic injury are all promising targets. Furthermore, mitochondrial therapy could revolutionize treatment paradigms in aging—a state intimately linked to mitochondrial decline—and other chronic conditions characterized by compromised cellular energetics.

Ultimately, this innovative research represents a leap forward in regenerative medicine and cellular bioengineering. Dr. Kusamori and his team’s work provides a rigorous scientific blueprint for developing mitochondrial therapy as a novel, precise, and powerful modality to restore cellular energy homeostasis. With continued investigation and refinement, mitochondrial transplantation holds the potential to transform clinical care for a spectrum of debilitating diseases, offering hope for treatments rooted in the restoration of life’s fundamental energy processes.

—

Subject of Research: Cells
Article Title: Uptake mechanisms and functions of isolated mitochondria in mesenchymal stromal cells
News Publication Date: 29-Dec-2025
References: DOI: 10.1038/s41598-025-28494-5
Image Credits: Associate Professor Kosuke Kusamori, Tokyo University of Science, Japan
Keywords: Mitochondria, Mesenchymal stromal cells, Mitochondrial transplantation, Cellular bioenergetics, Endocytosis, Regenerative medicine, Oxidative phosphorylation, Cellular respiration, Cell proliferation, Mitochondrial therapy, Neurodegenerative diseases, Mitochondrial dysfunction

One pioneering approach to studying the neural tube’s formation involves the utilization of human pluripotent stem (hPS) cells. These cells offer remarkable potential due to their ability to differentiate into various cell types, including neurons, thereby making them invaluable for modeling human neurodevelopment. Recent investigations have highlighted the benefits of employing hPS cells as a robust alternative to traditional animal models, expanding our understanding of neural differentiation and related pathologies. The power of these stem cells lies not only in their versatility but also in their capacity to reflect human-specific developmental processes that are often not accurately replicated in lower organisms.

Within this dynamic research landscape, microfluidic technologies have emerged as game-changers, offering innovative ways to mimic biological processes on a microscale. A recent study has introduced a microfluidic gradient device that allows scientists to model the formation and regional patterning of the neural tube using hPS cells. This device is ingeniously designed to facilitate the precise placement of hPS cell colonies within microfluidic channels, thereby encouraging the development of intricate tissue structures that resemble natural neural formations. Such technological advancements open avenues for constructing not only neural tube-like structures but also forebrain-like tissues, contributing significantly to our understanding of embryonic neurodevelopment.

The microfluidic device allows for the controlled application of chemical gradients, simulating the extracellular matrix conditions essential for the regional patterning of the human neural tube. Specifically, this innovation fosters the establishment of rostral–caudal and dorsal–ventral gradients. By creating a conducive environment for hPS cells, researchers can influence their differentiation paths, leading to the development of either microfluidic neural tube-like structures (μNTLS) or microfluidic forebrain-like structures (μFBLS). This precise control over environmental variables essentially recapitulates the natural influences that guide embryonic development, permitting researchers to explore and characterize various developmental stages in detail.

The μNTLS not only demonstrates the capacity for forming lumenal structures, but it also reveals the spatial organization characteristic of early human neural development. This structure allows the investigation of essential markers of development, showcasing distinct regional identities among cells. Importantly, the emergence of secondary signaling centers within the μNTLS mirrors critical processes observed during natural neural development. Additionally, the formation of neural crest cells represents another crucial achievement, unfolding the complexities inherit within human embryogenesis and highlighting the distinct trajectories taken by various cell types during early neural development.

Moreover, the μFBLS adds another dimension by showcasing the compartmentalization of dorsal and ventral regions, akin to what occurs in developing forebrain structures. This spatial segregation allows researchers to observe how early neurons emerge and become layered in relation to their progenitor cells. Consequently, the μFBLS provides more than just an experimental model; it serves as a dynamic platform for studying the cellular transitions vital for the development of the human forebrain pallium and subpallium, two areas essential for higher-order cognitive functions.

One of the most captivating features of this microfluidic approach is the feasibility of long-term culture, enabling continuous observation of developmental trajectories. Coupled with live imaging techniques, researchers can visualize dynamic cellular events over extended periods, providing insights into the mechanisms driving neural differentiation. Furthermore, through immunofluorescence staining, scientists can mark specific cellular populations, facilitating a more detailed examination of temporal changes in cell behavior and gene expression. This multiplicity of techniques further enhances the utility of μNTLS and μFBLS for dissecting the intricacies of neurodevelopment.

In addition to traditional methods, the advent of single-cell sequencing technologies allows for a deeper understanding of the heterogeneity within these developing neural tissues. By analyzing gene expression profiles at the single-cell level, researchers can discern the diverse cellular states present within both the μNTLS and μFBLS. This granularity in data collection enhances our ability to construct detailed maps of neural differentiation pathways, shedding light on how various factors contribute to the emergence of distinct neuronal populations and regional identities.

Importantly, this microfluidic gradient device and its applications encapsulate a significant advancement in our ability to study human neurodevelopment. Researchers equipped with knowledge in polydimethylsiloxane soft lithography and cell culture techniques can implement this protocol effectively, which typically takes between eight to forty-one days to yield results. The timeframe largely depends on the specific neural structures being modeled and their developmental stages, further testament to the versatility and adaptability of this research approach.

As the scientific community continues to explore the depths of human neurobiology, the implications of such innovations resonate beyond basic research. Understanding neural tube formation and related regional patterning may lead to significant breakthroughs in developing therapies for neural tube defects and other congenital disorders that arise from disruptions in embryonic development. As this exciting domain of research unfolds, the capacity to model human neural development in a controlled environment paves the way for pioneering advancements in regenerative medicine, ultimately enriching our comprehension of neural diseases and facilitating the design of targeted treatment strategies.

In conclusion, the integration of microfluidic technologies with hPS cell models represents a transformative leap in neurodevelopmental research. The generation of spatially patterned neural structures offers unprecedented opportunities to uncover the biological principles governing neural formation and migration. As the scientific community delves deeper into these microfluidic systems, they hold the potential to redefine our understanding of human brain development, offering new insights that may one day translate into improved interventions for neurodevelopmental disorders.

Amidst the intricate ballet of molecular and cellular interactions that underpin the formation of the human nervous system, these developments offer a glimpse into the future of biomedical science—where computational modeling, advanced engineering, and cellular biology converge to illuminate the complexities of life itself, fostering a new era of understanding and therapeutic potential.

Subject of Research: Neural Development Modeling using Microfluidic Gradient Devices

Article Title: Generation of spatially patterned human neural tube-like structures using microfluidic gradient devices

Article References:

Xue, X., Rahman, O.M., Sun, S. et al. Generation of spatially patterned human neural tube-like structures using microfluidic gradient devices.
Nat Protoc (2025). https://doi.org/10.1038/s41596-025-01266-1

Image Credits: AI Generated

DOI: 10.1038/s41596-025-01266-1

Keywords: Neural tube formation, human pluripotent stem cells, microfluidic devices, neurodevelopment, cellular modeling, gradient exposures, lumenal structures, live imaging, immunofluorescence, single-cell sequencing.

The complexity of delivering therapeutics such as nucleic acids, proteins, and gene-editing tools into specific internal organs has long posed a formidable challenge. Conventional methods largely depend on systemic circulation through the bloodstream, where off-target effects, systemic toxicity, and poor uptake efficiency often stymie therapeutic efficacy. The NanoFLUID patch circumvents these issues by integrating directly onto the organ surface, establishing a more direct and controlled interface that enhances intracellular delivery precision.

Central to the NanoFLUID’s functionality is its chipless architecture, which eschews bulky electronic components in favor of a thin, flexible platform comprising layered functional materials. This design flexibility allows the patch to conform seamlessly with the complex geometries of organs such as the liver, lungs, and tumors, minimizing tissue disruption and facilitating close contact necessary for effective payload transfer. Importantly, the elimination of rigid chips or batteries gives the system a lightweight and biocompatible profile amenable to prolonged implantation or repeated application.

At the heart of this device is a sophisticated nanopore-microchannel-microelectrode ensemble engineered to achieve controlled electroperforation of cell membranes. Unlike electroporation techniques requiring high voltages and causing extensive cell damage, the NanoFLUID operates under relatively low-amplitude electrical pulses around 20 volts. This refined electrical stimulation transiently perforates cellular membranes, enabling rapid intracellular payload entry without compromising viability. Remarkably, this electroperforation accelerates payload transport by approximately 100,000 times compared to passive diffusion, ensuring efficient delivery within minutes.

Extensive in vivo evaluations highlight the versatility and safety profile of the NanoFLUID patch across multiple therapeutic scenarios. In breast cancer models, application of the patch facilitated targeted gene transfection, enabling precise modulation of tumor cells while minimizing systemic exposure. Similarly, in liver injury models, the patch delivered reparative molecules directly to damaged tissues, significantly enhancing healing outcomes. These studies collectively demonstrate the patch’s potential as a robust platform for both preclinical research and clinical therapy.

An especially compelling application of the NanoFLUID involves functional genomics screening within living organisms. By delivering a comprehensive gene library directly into the tumor microenvironment, researchers performed in vivo transfection to identify critical drivers of metastasis. This approach led to the discovery of DUS2 as a pulmonary metastasis driver in breast cancer, illuminating novel biological pathways for targeted drug development. This capability to perform high-throughput, organ-specific genetic screens in situ provides a powerful tool to unravel disease mechanisms that would be challenging with systemic or ex vivo methods.

The battery-free feature of the NanoFLUID addresses a common limitation in implantable biomedical devices where power sources restrict size, flexibility, and implantation longevity. By harnessing external electrical stimuli and the device’s intrinsic nanofluidic architecture, therapeutic delivery is not only rendered wireless but also precisely controllable in temporal and spatial dimensions. Users can customize dosage, timing, and payload composition, adapting treatment regimens dynamically to patient needs or therapeutic feedback.

Further technical refinement has enabled the NanoFLUID to be manufactured from biocompatible materials ensuring minimal immune response and excellent mechanical durability within the harsh physiological environment. Its soft, stretchable layers endure organ movement and expansion without compromising the intimate interface with target cells. This durability is critical for chronic conditions requiring repeated or sustained drug administration, promising enhanced patient comfort and compliance.

Mechanistically, the nanopores within the patch act as conduits, guiding therapeutic molecules through microchannels positioned in close proximity to the target organ’s cell membranes. Coupled with microelectrodes strategically embedded to generate mild electric fields, this system facilitates the transient opening of membrane pores, allowing charged or neutral payloads to enter the cytoplasm effectively. This interplay of nanofluidics and bioelectronics represents a pioneering convergence of disciplines advancing precision medicine.

Beyond cancer therapy and tissue repair, the use-cases of NanoFLUID extend to rare genetic disorders amendable by in vivo gene editing techniques like CRISPR-Cas systems. The patch could serve as a local enhancer of gene-editing efficiency, mitigating systemic off-target effects and immune challenges that currently limit clinical adoption. Its chipless nature also simplifies regulatory pathways, potentially accelerating translational timelines.

Overall, the advent of the NanoFLUID patch heralds a new era of bioelectronic medicine, where therapeutic delivery is no longer constrained by systemic barriers, power budgets, or mechanical incompatibilities. By merging nanoengineering, fluid dynamics, and electrophysiology, this technology enables smart, safe, and selective intracellular access to organs previously out of reach. Such capability opens avenues for more personalized treatments, improved drug screening workflows, and deeper biological insights.

Moving forward, optimizing the NanoFLUID for human application will involve scaling manufacturing and conducting comprehensive safety and efficacy trials. Integration with existing implantable medical devices may also facilitate multi-modal therapies combining electrical, chemical, and biological interventions. Furthermore, coupling the patch with real-time biosensors could create closed-loop systems for responsive drug delivery, enhancing therapeutic precision.

In conclusion, the NanoFLUID patch embodies a leap forward for organ-targeted therapeutics, presenting an elegant, battery-free platform that drastically improves the rate and control of intracellular payload delivery. Its ability to deliver diverse biomolecules safely and efficiently positions it as a pivotal tool in the fight against cancer, genetic diseases, and acute organ injuries. By enabling detailed genetic interrogation in vivo and precise manipulation of tissue environments, NanoFLUID stands to revolutionize both treatment paradigms and fundamental biological research alike.

Subject of Research:
Targeted intracellular delivery systems; bioelectronic interfaces for internal organ therapeutics; nanofluidic drug delivery platforms.

Article Title:
A battery-free nanofluidic intracellular delivery patch for internal organs

Article References:
Yin, D., Wang, P., Hao, Y. et al. A battery-free nanofluidic intracellular delivery patch for internal organs. Nature (2025). https://doi.org/10.1038/s41586-025-08943-x

Image Credits:
AI Generated